 |
6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dione |
|---|---|
| Trade Name | |
| Orphan Indication | Symptomatic obstructive hypertrophic cardiomyopathy |
| USA Market Approval | USA |
| USA Designation Date | 2016-04-27 00:00:00 |
| Sponsor | MyoKardia, Inc.;333 Allerton Avenue;South San Francisco, California, 94080 |
